HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC
Hepatic arterial infusion chemotherapy (HAIC) deliver high concentration of chemotherapeutic agents directly to the liver tumor, was proved to be effective for intrahepatic and perihilar cholangiocarcinoma. Based on the potential synergistic effect of bevacizumab, chemotherapy and PD-1 inhibitor, this phase II clinical study want to test the efficacy and safety using intra-arterial infusion of oxaliplatin, 5-fluorouracil and bevacizumab combined with intravenous infusion of PD-1 inhibitor (Toripalimab) in the treatment of unresectable biliary malignant tumors.
Advanced Biliary Tract Cancer
DRUG: OXA, 5-FU and bevacizumab plus Toripalimab
Overall response rate, CR plus PR according to imRECIST, From the start of treatment until the end of treatment, up to approximately 3 years
Overall survival, date from the start of treatment until death or lost to follow-up, whichever happen first, assessed at least 6 months, From the start of treatment until death or lost to follow-up, up to approximately 3 years|Adverse events, type and incidence of adverse events, From the start of treatment until the end of treatment, up to approximately 3 years|Progression-free survival, date from the first treatment to the date of disease progression, lost to follow-up or death, whichever happen first, From the start of the treatment until first documented progression or death from any cause, whichever came first, assessed up to approximately 3 yearsse date of disease progression
Hepatic arterial infusion chemotherapy (HAIC) deliver high concentration of chemotherapeutic agents directly to the liver tumor, was proved to be effective for intrahepatic and perihilar cholangiocarcinoma. Based on the potential synergistic effect of bevacizumab, chemotherapy and PD-1 inhibitor, this phase II clinical study want to test the efficacy and safety using intra-arterial infusion of oxaliplatin, 5-fluorouracil and bevacizumab combined with intravenous infusion of PD-1 inhibitor (Toripalimab) in the treatment of unresectable biliary malignant tumors.